Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Side Effects of the Dose-1 of Astrazeneca and Sinopharm Vaccines in Patients With Multiple Sclerosis in Kermanshah, Iran (2021) Publisher



Razazian N1, 2 ; Sahraian MA3 ; Rezaei M4 ; Eskandarieh S3 ; Khamoushian K5 ; Mousavi SE1, 2 ; Fakhri N2, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  2. 2. Neuroscience Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
  3. 3. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
  5. 5. Clinic of Multiple Sclerosis, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  6. 6. Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

Source: Current Journal of Neurology Published:2023


Abstract

Background: Coronavirus 2019 (COVID-19) vaccination is recommended for people with multiple sclerosis (MS). This study evaluated the side effects of Sinopharm and AstraZeneca vaccines in MS patients. Methods: In this cross-sectional study among MS patients in Kermanshah province, Iran, who received Sinopharm or AstraZeneca vaccine, sampling was performed through convenience sampling according to the nationwide MS registry of Iran (NMSRI). Demographic and clinical information of the participants and data on the side effects of vaccines were collected by telephone after the first dose. The data were analyzed in SPSS software. Results: 264 vaccinated MS patients (217 with Sinopharm and 47 with AstraZeneca) were studied. In the Sinopharm and AstraZeneca groups, respectively, 58.5% and 73.3% of patients had side effects that were not significantly different between the 2 groups (P = 0.064). In the AstraZeneca group, the severity of side effects and prevalence of taking painkillers were significantly higher (P < 0.050) and the interval between vaccination and side effects onset was significantly shorter (P = 0.013). The most commonly experienced side effects in the Sinopharm group were fatigue (29.0%), myalgia (24.9%), fever (24.0%), and headache (21.7%), and in the AstraZeneca group were fever (59.6%), chills (51.1%), myalgia (40.4%), and fatigue (34.0%). Logistic regression by controlling for confounding variables showed that considering some factors as confounding factors did not show a significant difference between the 2 vaccines in the experience of side effects (P = 0.104). Conclusion: The AstraZeneca vaccine caused more severe side effects in MS patients than the Sinopharm vaccine. Most of the side effects were moderate in severity and transient. © 2023 Iranian Neurological Association, and Tehran University of Medical Sciences Published by Tehran University of Medical Sciences.
Related Docs
View other Related Docs
1. Side Effects of First and Second Doses of Inactivated Covid-19 Vaccine in Multiple Sclerosis, Caspian Journal of Neurological Sciences (2023)
2. Follow-Up of Patients With Multiple Sclerosis After Covid-19 Vaccination With Sinopharm Vaccine, Caspian Journal of Neurological Sciences (2023)
3. Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020), Multiple Sclerosis and Related Disorders (2022)
4. Comparison of Astrazeneca and Sinopharm Vaccines As Boosters in Protection Against Covid-19 Infection, Biologicals (2023)
5. Short-Term Safety of Covaxin, Sinopharm, Sputnik V, and Astrazeneca Covid-19 Vaccines Among Iranian Healthcare Workers: A Cross-Sectional Study, Archives of Clinical Infectious Diseases (2024)
6. The Risk of Confusion Between Astrazeneka Covid-19 Vaccine Side Effects and Signs of Covid-19 Infection: A Case Report, Clinical and Experimental Vaccine Research (2022)
7. Safety and Immunogenicity of a Recombinant Receptor-Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine™) Against Covid-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial, Journal of Medical Virology (2023)
8. Cutaneous Adverse Reactions Following Covid-19 Vaccinations: A Systematic Review and Meta-Analysis, Journal of Cosmetic Dermatology (2022)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (5)
Sharareh Eskandarieh (4)
Other Related Docs
9. Efficacy and Safety of an Inactivated Virus-Particle Vaccine for Sars-Cov-2, Biv1-Coviran: Randomised, Placebo Controlled, Double Blind, Multicentre, Phase 3 Clinical Trial, BMJ (2023)
10. Sputnik V Vaccine-Related Complications and Its Impression on Inflammatory Biomarkers in Healthcare Providers, Indian Journal of Medical Microbiology (2023)
11. The Study of Covid-19 Infection Following Vaccination in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
12. Side Effects and Short-Term Safety of Covid-19 Vaccines for Pregnant Women: A Case Study of Southeast Iran, Archives of Clinical Infectious Diseases (2023)
13. Outcomes of Astrazeneca Vaccine for Relapse and Covid-19 Infection in People With Multiple Sclerosis; [پیامدهاي واکسن آسترازنکا در ابتلا به کووید- 19 و عود در افراد مبتلا به مالتیپل اسکلروزیس], Tehran University Medical Journal (2022)